Citations

Clear

1446 citation(s) found for "Howard, F".

Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk
Ghoneim, Dalia, Zhu, Jingjing , Murff, Harvey J. , Ye, Fei , Khankari, Nikhil K. , Haycock, Philip , Antwi, Samuel O. , Yang, Yaohua , Arslan, Alan A. , Bracci, Paige M. , Du, Mengmeng , Gallinger, Steven , Goodman, Phyllis J. , Scélo, Ghislaine , Visvanathan, Kala , Andreotti, Gabriella , Babić, Ana , Berndt, Sonja I. , Brennan, Paul , Bueno‐de‐Mesquita, Bas , Buring, Julie E. , Rabe, Kari G. , Duggal, Priya , Fuchs, Charles S. , Gaziano, J. Michael , Hackert, Thilo , Hassan, Manal M. , Helzlsouer, Kathy J. , Holly, Elizabeth A. , Hoover, Robert N. , Katske, Verena, Kurtz, Robert C. , Lee, I‐Min , Murphy, Neil , Oberg, Ann L. , Porta, Miquel , Rothman, Nathaniel , Sesso, Howard D. , Wactawski‐Wende, Jean , Wentzensen, Nicolas , Wolpin, Brian M. , Jacobs, Eric J. , Petersen, Gloria M. , Stolzenberg-Solomon, Rachel Z., Wu, Lang , Haycock, Philip , Arslan, Alan A , Canzian, Federico , Giles, Graham G , Visvanathan, Kala , Bamlet, William R , Brennan, Paul , Chaffee, Kari G. , Hackert, Thilo , Katzke, Verena , Malats, Nuria , Milne, Roger L , Oberg, Ann L , Sesso, Howard D , Wactawski-Wende, Jean , Yu, Herbert , Duell, Eric J , Amundadottir, Laufey , Klein, Alison P , Antwi, Samuel O , Murphy, Neil , Porta, Miquel , Duggal, Priya , Zheng, Wei , Long, Jirong , Setiawan, Veronica Wendy , Wilkens, Lynne R. , Freeman, Laura E. Beane , Canzian, Federico , Giles, Graham G. , Kooperberg, Charles , Marchand, Loı̈c Le , Neale, Rachel Ε. , White, Emily , Albanes, Demetrius , Amiano, Pilar , Bamlet, William R. , Brais, Lauren K , Campbell, Peter T. , Chanock, Stephen Jacob , Goggins, Michael , Malats, Núria , Milne, Roger L. , Rothman, Nathaniel , Silverman, Debra T. , Thompson, Ian M. , Wang, Xiaoliang , Yu, Kai , Zeleniuch‐Jacquotte, Anne , Duell, Eric J. , Risch, Harvey A. , Ámundadóttir, Laufey T. , Kraft, Peter , Klein, Alison P. , Shu, Xiao‐Ou , Yang, Yaohua

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 23, 2020 | Volume: 29 | Issue: 12 | Pages: 2735-2739

10.1158/1055-9965.epi-20-0651 | PMID 32967863 Get It

Abstract Background: Whether circulating polyunsaturated fatty acid (PUFA) levels are associated with pancreatic cancer risk is uncertain. Mendelian randomization (MR) represents a study design using genetic instruments to better characterize the relationship between exposure and outcome. Methods: We utilized data from genome-wide association studies within the Pancreatic Cancer Cohort Consortium and Pancreatic Cancer Case–Control Consortium, involving approximately 9,269 cases and 12,530 controls of European descent, to evaluate associations between pancreatic cancer risk and genetically predicted plasma n-6 PUFA levels. Conventional MR analyses were performed using individual-level and summary-level data. Results: Using genetic instruments, we did not find evidence of associations between genetically predicted plasma n-6 PUFA levels and pancreatic cancer risk [estimates per one SD increase in each PUFA-specific weighted genetic score using summary statistics: linoleic acid odds ratio (OR) = 1.00, 95% confidence interval (CI) = 0.98–1.02; arachidonic acid OR = 1.00, 95% CI = 0.99–1.01; and dihomo-gamma-linolenic acid OR = 0.95, 95% CI = 0.87–1.02]. The OR estimates remained virtually unchanged after adjustment for covariates, using individual-level data or summary statistics, or stratification by age and sex. Conclusions: Our results suggest that variations of genetically determined plasma n-6 PUFA levels are not associated with pancreatic cancer risk. Impact: These results suggest that modifying n-6 PUFA levels through food sources or supplementation may not influence risk of pancreatic cancer.
Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance)
Innocenti, Federico , Sibley, Alexander B. , Patil, Sushant, Etheridge, Amy S. , Jiang, Chen , Ou, Fang‐Shu , Howell, Stefanie , Plummer, Sarah J. , Bertagnolli, Monica M. , McLeod, Howard L. , Auman, J. Todd , Blanke, Charles D. , Furukawa, Yoichi , Kubo, Michiaki , Lenz, Heinz‐Josef , Ratain, Mark J. , Owzar, Kouros , Bertagnolli, Monica M , McLeod, Howard L , Auman, James T , Furukawa, Yoichi , Venook, Alan P , Kubo, Michiaki , Lenz, Heinz-Josef , Parker, Joel S , Ou, Fang-Shu , Casey, Graham , Venook, Alan P. , Parker, Joel S.

Mayo Clinic

Clinical Cancer Research | September 21, 2020 | Volume: 27 | Issue: 1 | Pages: 267-275

10.1158/1078-0432.ccr-20-2021 | PMID 32958699 Get It

Abstract Purpose: Irinotecan/5-fluorouracil (5-FU; FOLFIRI) or oxaliplatin/5-FU (FOLFOX), combined with bevacizumab or cetuximab, are approved, first-line treatments for metastatic colorectal cancer (mCRC). We aimed at identifying germline variants associated with survival in patients with mCRC treated with these regimens in Cancer and Leukemia Group B/SWOG 80405. Experimental Design: Patients with mCRC receiving either FOLFOX or FOLFIRI were randomized to either cetuximab or bevacizumab. DNA from peripheral blood was genotyped for approximately 700,000 SNPs. The association between SNPs and overall survival (OS) was tested in 613 patients of genetically estimated European ancestry using Cox proportional hazards models. Results: The four most significant SNPs associated with OS were three haplotypic SNPs between microsomal glutathione S-transferase 1 (MGST1) and LIM domain only 3 (LMO3, representative HR, 1.56; P = 1.30 × 10−6), and rs11644916 in AXIN1 (HR, 1.39, P = 4.26 × 10−6). AXIN1 is a well-established tumor suppressor gene in colorectal cancer, and rs11644916 (G>A) conferred shorter OS. Median OS for patients with the AA, AG, or GG genotypes was 18.4, 25.6, or 36.4 months, respectively. In 90 patients with stage IV colorectal cancer from The Cancer Genome Atlas (TCGA), rs11649255 in AXIN1 [in almost complete linkage disequilibrium (LD) with rs11644916], was associated with shorter OS (HR, 2.24, P = 0.0096). Using rs11648673 in AXIN1 (in very high LD with rs11644916 and with functional evidence), luciferase activity in three colorectal cancer cell lines was reduced. Conclusions: This is the first large genome-wide association study ever conducted in patients with mCRC treated with first-line standard treatment in a randomized phase III trial. A common SNP in AXIN1 conferred worse OS and the effect was replicated in TCGA. Further studies in colorectal cancer experimental models are required.
Rationale, Design, and Implementation of Intensive Risk Factor Treatment in the CREST2 Trial
Turan, Tanya N. , Voeks, Jenifer H. , Chimowitz, Marc I. , Roldan, Ana , LeMatty, Todd, Lopes‐Virella, Maria F. , Chaturvedi, Seemant , Jones, Michael R. , Heck, Donald , Lal, Brajesh K. , Brott, Thomas G. , Haley, William E. , Howard, George , Meschia, James F.

Mayo Clinic

Stroke | September 21, 2020 | Volume: 51 | Issue: 10 | Pages: 2960-2971

10.1161/strokeaha.120.030730 | PMID 32951538 Get It

Background and Purpose: The CREST2 trial (Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis) is comparing intensive medical management (IMM) alone to IMM plus revascularization with carotid endarterectomy or transfemoral carotid artery stenting for preventing stroke or death within 44 days after randomization or ipsilateral ischemic stroke thereafter. There are extensive clinical trial data on outcomes after revascularization of asymptomatic carotid stenosis, but not for IMM. As such, the experimental treatment in CREST2 is IMM, which is described in this article. Methods: IMM consists of aspirin 325 mg/day and intensive risk factor management, primarily targeting systolic blood pressure <130 mm Hg (initially systolic blood pressure <140 mm Hg) and LDL (low-density lipoprotein) cholesterol <70 mg/dL. Secondary risk factor targets focus on tobacco smoking, non-HDL (high-density lipoprotein), HbA1c (hemoglobin A1c), physical activity, and weight. Risk factor management is performed by site personnel and a lifestyle coaching program delivered by telephone. We report interim risk factor data on 1618 patients at baseline and last follow-up through 24 months. Results: The mean baseline LDL of 80.5 mg/dL improved to 66.7 mg/dL. The mean baseline systolic blood pressure of 139.7 mm Hg improved to 130.3 mm Hg. The proportion of patients in-target improved from 43% to 61% for systolic blood pressure <130 mm Hg and from 45% to 67% for LDL<70 mg/dL (both changes P <0.001). Conclusions: The rigorous multimodal approach to intensive stroke risk factor management in CREST2 has resulted in significant improvements in risk factor control that will enable a comparison of cutting-edge medical care to revascularization in patients with asymptomatic carotid stenosis. Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT02089217.
First-line medication dosing in pediatric refractory status epilepticus
Vasquez, Alejandra , Gaínza‐Lein, Marina , Amengual‐Gual, Marta , Anderson, Anne E. , Arya, Ravindra , Brenton, J. Nicholas , Carpenter, Jessica L. , Chapman, Kevin , Clark, Justice , Farias‐Moeller, Raquel , Gaillard, William D. , Goldstein, Joshua , Goodkin, Howard P. , McDonough, Tiffani L. , Mikati, Mohamad A. , Morgan, Lindsey A. , Ostendorf, Adam P. , Payne, Eric T. , Peariso, Katrina , Piantino, Juan , Riviello, James J. , Sannagowdara, Kumar , Tasker, Robert C. , Tchapyjnikov, Dmitry , Topjian, Alexis , Wainwright, Mark S. , Wilfong, Angus A. , Williams, Korwyn, Kelley, Sarah A. , Stafstrom, Carl E. , Kossoff, Eric H. , Lewis, Dalila, Stanfield, Tony, Sculier, Claudine , Sansevere, Arnold J. , Sacco, Melissa, Duncan, Abby, McCoy, Jordan, DaSilva-Chiodo, Kathryn, Faist, Robert, Santel, D., LaFay, Victor , Clark, Peggy O., Borror, Sarah, Debs, Andrea, Clohessy, Caitlin, Weber, Amanda , Yuliati, Asri, Luat, Aimée F. , Singh, Azara, Helseth, Ashley , Fernandes, Cecilia, Tran, Linh , McLean, Melissa, Nayak, Anuranjita , Hecox, Kurt, Nallamothu, R. K., Rehborg, Rebecca, Goldstein, David B., Cox, Erin Heinzen, Malone, Colin D., Thornburg, Olivia , Basma, Natasha, Burrows, Brian T., Dyar, Beata, Mishler, Laura, Lee‐Eng, Jacqueline , Streb, Madison, Ganesan, Saptharishi Lalgudi , Huh, Linda , Martic, Nela, Abend, Nicholas S. , Amengual-Gual, Marta, Anderson, Anne, Arya, Ravindra , Brenton, J Nicholas , Farias-Moeller, Raquel, Glauser, Tracy, Goldstein, Joshua L, Guerriero, Rejean M , Kapur, Kush , Lai, Yi‐Chen , Novotny, Edward J , Payne, Eric T , Tasker, Robert C , Tchapyjnikov, Dmitry , Wainwright, Mark S , Wilfong, Angus, Loddenkemper, Tobias , Gaillard, William D , Mikati, Mohamad A , Morgan, Lindsey A , Glauser, Tracy A. , Novotny, Edward J. , Bansal, Seema, Habela, Christa Whelan , Aguilar, Cristina Barcia , Santel, Daniel, LaFay, Victor, Turner, David A. , Nallamothu, Rupa, Grinspan, Zachary M. , Appavu, Brian , Hahn, Cecil D.

Mayo Clinic

Neurology | September 11, 2020 | Volume: 95 | Issue: 19 | Pages: No page available

10.1212/wnl.0000000000010828 | PMID 32913024 Get It

Abstract 6267: Repurposing antiandrogens to overcome therapy resistance in androgen receptor-positive glioblastoma
Werner, Christian K. , Nna, Uchechi J. , Sun, Hanshi, Wilder-Romans, Kari , Dresser, Joseph, Kothari, Ayesha U. , Zhou, Weihua , Yao, Yangyang , Rao, Arvind , Stallard, Stefanie, Bor, Tarik , Debinski, Waldemar, Hegedus, Alexander M. , Morgan, Meredith A. , Venneti, Sriram , Baskin-Bey, E., Spratt, Daniel , Colman, Howard, Chinnayain, Arul, Lawrence, Theodore S. , Wahl, Daniel , Lawrence, Theodore S , Kothari, Ayesha U , Koschmann, Carl , Spratt, Daniel, Colman, Howard , Sarkaria, Jann N. , Eisner, Joel Robert , Speers, Corey , Strowd, Roy E.

Mayo Clinic

Cancer Research | September 4, 2020 | Volume: 80 | Issue: 16_Supplement | Pages: 6267-6267

10.1158/1538-7445.am2020-6267 Get It

Abstract New approaches are needed to overcome intrinsic therapy resistance in glioblastoma (GBM). Because GBMs exhibit sexual dimorphism and are reported to express steroid hormone receptors, we reasoned that signaling through the androgen receptor (AR) could mediate therapy resistance in GBM, as it does in AR-positive prostate and breast cancers. Using RNAseq, immunoblot and immunohistochemistry, we found that nearly half of GBM cell lines, patient-derived xenografts and human tumors express AR transcript and protein with levels that overlap those of primary prostate cancer. AR expression in GBM did not vary by sex, age or common molecular alterations. We identified two cell line models of GBM that expressed AR protein (LN18 and T98G: termed “AR positive”) and two that did not (8MGBA and AM38: termed “AR negative”). Seviteronel, a blood-brain barrier permeable CYP17 lyase inhibitor and antiandrogen slowed growth in AR positive GBM cell lines (GI50 3-4 µM) but not AR negative lines (GI50 &gt; 500 µM) as measured by the colony formation assay. The antiandrogen enzalutamide, which also penetrates the blood brain barrier, similarly preferentially slowed growth in AR positive GBM cell lines. Seviteronel and enzalutamide sensitized AR positive GBM cell lines to radiation with enhancement ratios of 1.3-1.6 as measured by the clonogenic survival assay. Antiandrogens had no effect on the radiosensitivity of AR negative GBM cell lines. Seviteronel treatment did not affect the growth of AR positive T98G xenografts grown in vivo, but did sensitize these tumors to radiation (median time to tripling: 15 d with radiation alone and not reached with radiation combined with seviteronel). Enzalutamide similarly had modest single agent effects on an AR positive GBM patient-derived xenograft (GBM26 from the Mayo Clinic GBM PDX national resource) grown in vivo but sensitized these tumors to radiation (median time to tripling: 25.5 d with radiation alone and 39 d with radiation combined with enzalutamide). RNAseq performed on GBM26 tumors grown in vivo revealed that enzalutamide treatment caused minimal transcriptional changes when given as monotherapy but, when given in combination with radiation, blocked the ability of AR-positive GBMs to engage adaptive transcriptional programs related to multiple DNA repair pathways. We confirmed these mechanistic findings in vitro, as antiandrogens selectively impaired the repair of radiation-induced double strand DNA breaks in AR positive GBM cell lines. These results suggest that AR signaling may mediate therapy resistance in AR positive GBMs, and patients with these tumors could derive clinical benefit from combination therapies involving radiation and blood-brain-barrier permeable antiandrogens. Citation Format: Christian K. Werner, Uchechi Nna, Hanshi Sun, Kari Wilder-Romans, Joseph Dresser, Ayesha Kothari, Weihua Zhou, Yangyang Yao, Arvind Rao, Stefanie Stallard, Carl Koschmann, Tarik Bor, Waldemar Debinski, Alexander Hegedus, Meredith Morgan, Sriram Venneti, Edwina Baskin-Bey, Daniel Spratt, Howard Colman, Jann Sarkaria, Arul Chinnayain, Joel Eisner, Corey Speers, Theodore S. Lawrence, Roy Strowd, Daniel R. Wahl. Repurposing antiandrogens to overcome therapy resistance in androgen receptor-positive glioblastoma [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 6267.
Radiologic and Pathologic Correlation in EVALI
Panse, Prasad M., Feller, Fionna , Butt, Yasmeen M. , Larsen, Brandon T. , Tazelaar, Henry D. , Harvin, Howard J. , Smith, Maxwell L. , Tazelaar, Henry D. , Gotway, Michael B.

Mayo Clinic

American Journal of Roentgenology | September 2, 2020 | Volume: 215 | Issue: 5 | Pages: 1057-1064

10.2214/ajr.20.22836 | PMID 32877245 Get It

Abstract PR05: A meta-analysis of genome-wide association study and eQTL analysis of multiple myeloma among African Americans
Du, Zhaohui , Weinhold, Niels , Song, Gregory, Rand, K.A., Hwang, Amie E. , Sheng, Xin , Hom, Victor, Pawlish, Karen , Peters, Edward , Mohrbacher, Ann, Stram, Alexander , Berndt, Sonja I. , Blot, William J. , Stevens, Victoria L. , Goodman, Phyllis J. , Hennis, Anselm , Nemesure, Barbara , Stanford, Janet L. , Witte, John S. , Signorello, Lisa B., John, Esther M. , Stroup, Antoinette M. , Zangari, Maurizio , Zheng, Wei , Hu, Jennifer J. , Carpten, John D. , Mehta, Jayesh, Wolf, Jeffrey L. , Martin, Thomas G. , Terebelo, Howard R. , Janakiraman, Nalini, Kolonel, Laurence N. , Auclair, Daniel , Vij, Ravi , Bernal‐Mizrachi, Leon , Zonder, Jeffrey A. , Huff, Carol Ann , Conti, David V. , Haiman, Christopher A. , John, Esther M , Zheng, Wei , Conti, David V , Berg, David Van Den , Ailawadhi, Sikander , Nooka, Ajay K. , Singhal, Seema , Bock, Cathryn Hufford , Stram, Alex , Casey, Graham , Kittles, Rick A. , Diver, W. Ryan , Klein, Eric A. , Rybicki, Benjamin A. , Bernstein, Leslie , Stephens, Owen , Rhee, Frits van , Olshan, Andrew F. , Ziegler, Regina G. , Nyante, Sarah J. , Ingles, Sue A. , Press, Michael F. , Chanock, Stephen Jacob , Colditz, Graham A. , Tomasson, Michael H. , Fiala, Mark A. , Anderson, Kenneth C. , Marchand, Loı̈c Le , Chiu, Brian C.‐H. , Ziv, Elad , Stram, Daniel O. , Morgan, Gareth J. , Lonial, Sagar , Orlowski, Robert Z. , Cozen, Wendy

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 1, 2020 | Volume: 29 | Issue: 6_Supplement_2 | Pages: PR05-PR05

10.1158/1538-7755.disp19-pr05 Get It

Abstract Background: Persons of African ancestry (AA) experience a 1.5-2-fold risk of multiple myeloma (MM) compared to persons of European ancestry (EA). We assembled a set of MM patients with self-reported AA in order to evaluate the contribution of genetics to etiology in this high-risk group. Methods: Here we present the results of a meta-analysis of two GWAS in 1,813 cases and 8,871 controls of AA. We also conducted an admixture mapping scan to identify risk alleles associated with local ancestry, fine-mapped the 23 known susceptibility loci to find markers that could better capture MM risk in individuals of AA, and constructed a polygenic risk score (PRS) to assess the aggregated effect of known MM risk alleles. Finally, we conducted an eQTL analysis measuring gene expression in those genes harboring a risk variant in malignant plasma cells from 292 of the patients from a single site. Results: In GWAS analysis, we identified two suggestive novel loci located at 9p24.3 and 9p13.1 at P&lt;1 × 10-6, but no genome-wide significant association was noted. In admixture mapping, we observed a genome-wide significant inverse association between local AA at 2p24.1-23.1 and MM risk in AA individuals. 20 of the 23 known EA risk variants showed directional consistency and 9 replicated at P&lt;0.05 in AA individuals. In eight regions, we identified markers that better capture MM risk in persons of AA. AA individuals with a PRS in the top 10% had a 1.82-fold (95%CI: 1.56, 2.11) increased MM risk compared to those with average risk (25-75%). The strongest functional association was between the risk allele for variant rs56219066 at 5q15 and lower ELL2 expression (P= 5.1 × 10–12). Conclusion: Our study shows that common genetic variation contributes to MM risk individuals of AA. This abstract is also being presented as Poster C040. Citation Format: Zhaohui Du, Niels Weinhold, Gregory Chi Song, Kristen A. Rand, David J. Van Den Berg, Amie E. Hwang, Xin Sheng, Victor Hom, Sikander Ailawadhi, Ajay K. Nooka, Seema Singhal, Karen Pawlish, Edward Peters, Cathryn Bock, Ann Mohrbacher, Alexander Stram, Sonja I. Berndt, William J. Blot, Graham Casey, Victoria L. Stevens, Rick Kittles, Phyllis J. Goodman, W. Ryan Diver, Anselm Hennis, Barbara Nemesure, Eric A. Klein, Benjamin A. Rybicki, Janet L. Stanford, John S. Witte, Lisa Signorello, Esther M. John, Leslie Bernstein, Antoinette Stroup, Owen W. Stephens, Maurizio Zangari, Frits Van Rhee, Andrew Olshan, Wei Zheng, Jennifer J. Hu, Regina Ziegler, Sarah J. Nyante, Sue Ann Ingles, Michael Press, John David Carpten, Stephen Chanock, Jayesh Mehta, Graham A Colditz, Jeffrey Wolf, Thomas G. Martin, Michael Tomasson, Mark A. Fiala, Howard Terebelo, Nalini Janakiraman, Laurence Kolonel, Kenneth C. Anderson, Loic Le Marchand, Daniel Auclair, Brian C.-H. Chiu, Elad Ziv, Daniel Stram, Ravi Vij, Leon Bernal-Mizrachi, Gareth J. Morgan, Jeffrey A. Zonder, Carol Ann Huff, Sagar Lonial, Robert Z. Orlowski, David V. Conti, Christopher A. Haiman, Wendy Cozen. A meta-analysis of genome-wide association study and eQTL analysis of multiple myeloma among African Americans [abstract]. In: Proceedings of the Twelfth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2019 Sep 20-23; San Francisco, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2020;29(6 Suppl_2):Abstract nr PR05.
Pulmonary Injury Resulting from Vaping or e-Cigarette Use: Imaging Appearances at Presentation and Follow-up
Panse, Prasad M., Feller, Fionna , Butt, Yasmeen M. , Smith, Maxwell L. , Larsen, Brandon T. , Tazelaar, Henry D. , Harvin, Howard J. , Feller, Fionna F , Tazelaar, Henry D. , Smith, Maxwell , Gotway, Michael B.

Mayo Clinic

Radiology: Cardiothoracic Imaging | August 27, 2020 | Volume: 2 | Issue: 4 | Pages: e200081

10.1148/ryct.2020200081 | PMID 33778606 Get It

Letter: An International Investigation Into the COVID-19 Pandemic and Workforce Depletion in Highly Specialized Neurointerventional Units – Insights From Stroke Thrombectomy and Aneurysm Registry and Endovascular Neurosurgery Research Group
Alawieh, Ali , Kasab, Sami Al , Almallouhi, Eyad , Levitt, Michael R. , Jabbour, Pascal , Sweid, Ahmad , Starke, Robert M. , Wolfe, Stacey Q , Fragata, Isabel , Maier, Ilko , Matouk, Charles, Howard, Brian M. , Grossberg, Jonathan A , Cawley, M. F., Kan, Peter , Hafeez, Muhammad Ubaid , Singer, Justin, Crowley, R. Webster , Joshi, Krishna C. , Brinjikji, Waleed , Ogilvy, Christopher S. , Gomez‐Paz, Santiago , Veznedaroglu, Erol, Binning, Mandy J., Soomro, Jazba , Williamson, Richard , Chalhoub, Reda , Crosa, Roberto , Webb, Sharon, Psychogios, Marios, Ducruet, Andrew F. , Albuquerque, Felipe C. , Turner, Raymond, Casagrande, Walter, Leacy, Reade De , Fessler, Richard D., Osanai, Toshiya , Chowdhry, Shakeel , Schirmer, Clemens M. , Ringer, Andrew J. , Spiotta, Alejandro M , collaborators, STAR and ENRG, Savastano, Luis E., Gomez-Paz, Santiago , Crosa, Roberto , Levitt, Michael R , De Leacy, Reade , Schirmer, Clemens M , Almallouhi, Eyad , Hafeez, Muhammad U , Wolfe, Stacey Quintero , Fragata, Isabel , Howard, Brian M , Alawieh, Ali M , Ogilvy, Christopher S , Jabbour, Pascal , Saini, Vasu A , Fargen, Kyle M , Arthur, Adam Stephen , Goyal, Nitin , Cawley, Michael, Savastano, Luis , Levy, Elad I. , Waqas, Muhammad, Mokin, Maxim , Mascitelli, Justin R , Yoo, Albert J. , Grande, Andrew Walker , Psychogios, Marios‐Nikos , Majmundar, Neil J. , Al‐Mufti, Fawaz , Mocco, J , Park, Minhee , collaborators, STAR and ENRG

Mayo Clinic

Neurosurgery | August 24, 2020 | Volume: 87 | Issue: 6 | Pages: E697-E699

10.1093/neuros/nyaa415 | PMID 32893855 Get It